Will I lose weight on Mounjaro — and how much can I realistically expect?

You've done the reading, but what do the trial numbers actually mean for you?

The figures from SURMOUNT-1 are striking, but they come with important context. The trial ran for 72 weeks (roughly 18 months) and participants were also following a reduced-calorie diet and increased activity programme. The 20–21% average at 15mg is an average across thousands of adults; some lost more, some less. At 10mg the average was around 19.5%, and even 5mg produced meaningful reductions. Mounjaro's full clinical profile shows that substantial weight loss at lower doses is well documented, which matters for people who need to stay at a lower dose for tolerability reasons.

The SURMOUNT-1 results were published in the New England Journal of Medicine and formed the basis of NICE's recommendation (TA1026), so these are not marketing statistics. They are the numbers regulators and clinicians used to decide the medicine should be available. Worth knowing.

What the trial can't tell you is exactly where you'll land. Age, baseline weight, metabolic health, sleep quality, stress and how your gut happens to respond to tirzepatide all influence outcomes. A realistic expectation: steady, measurable weight loss that tends to accelerate as the dose increases, with most of the total loss happening in the first year.

Why Mounjaro produces weight loss, the mechanism matters for setting expectations

Understanding how Mounjaro works helps explain both why it tends to be effective and why it takes time. Tirzepatide activates two gut-hormone receptors: GIP and GLP-1. Both are involved in regulating appetite and blood sugar. Activating them together slows how quickly food leaves your stomach, raises feelings of fullness after eating, and reduces the background drive to eat between meals. The biology behind why Mounjaro causes weight loss is genuinely interesting, and knowing it helps people understand why eating smaller portions feels natural rather than forced after the first few weeks.

This dual action is what sets tirzepatide apart from GLP-1-only medicines. It is the only dual-agonist licensed for weight management in the UK. That said, the mechanism means the medicine works best when you're working with it: protein-rich meals, staying hydrated, and keeping active all help the biology do its job.

Treatment starts at 2.5mg. That opening dose is there to let your system adjust, not to produce rapid weight loss, so if the first four weeks feel underwhelming, that's expected. The prescriber titrates the dose every four weeks or so from there. When weight loss typically starts on Mounjaro is a question many people have early on, and the honest answer is: usually within the first month, but the more significant changes come as the dose climbs.

What can reduce how much weight you lose, and what to do if progress stalls

Some people lose less than the trial averages, and there are identifiable reasons. Staying at a lower dose because of side effects, not following the lifestyle guidance alongside the injections, or having an underlying condition that affects metabolism can all slow progress. It's also worth knowing that a small number of people don't respond as expected, what to do if Mounjaro isn't producing weight loss is something our clinical team reviews before any repeat prescription.

NICE's guidance (TA1026) notes that if someone loses less than 5% of their body weight after six months at the highest tolerated dose, the prescriber reviews whether continuing makes sense. That clinical checkpoint exists to protect patients, not to write them off. Sometimes the answer is adjusting the lifestyle programme; sometimes it's investigating an underlying cause. Either way, a prescriber is part of that conversation.

If you're already tracking your dose titration and wondering how to get the most from treatment, the practical guidance on supporting weight loss on Mounjaro covers the lifestyle factors that the trial participants also followed. There's also a useful cost context page (how Mounjaro prices compare across UK providers) if you're weighing up your options before committing to a prescription service.

Starting treatment: what the prescriber assesses, and what comes next

Mounjaro is licensed for adults with a BMI of 30 or above, or 27 and above alongside a weight-related condition such as high blood pressure, high cholesterol, or obstructive sleep apnoea. Lower BMI thresholds may apply for some ethnic backgrounds under UK clinical guidance. BMI alone doesn't guarantee a prescription, the prescriber looks at your full health picture, current medicines, and any contraindications before approving treatment.

At nume, a GPhC-registered Independent Prescriber reads every consultation personally on the same day it's submitted. There's no algorithm making the call. If you order by midday on a working day and your prescription is approved, your treatment is dispatched the same day and arrives free the next working day via DPD, in plain packaging. You can read more about how the service works or check the consultation process via our treatment page.

One practical note from our prescribers: many patients tell us they were nervous about starting because the trial figures felt too good to be true. The evidence is solid (it's published, peer-reviewed and the basis of a NICE recommendation) but it does take time, consistency and clinical oversight to achieve. That combination is the point of a supervised service, not just the prescription itself. The clinical team is there throughout, not just at sign-up. If you have questions before starting, the FAQs page covers the most common ones.